A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

A “game-changing” new Alzheimer’s treatment was approved for use in the US by “independent” scientists who had received ...

The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...

The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

Lilly said Japan is the second major market in which the drug has received approval, after the United States where it is sold ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...